Use of posaconazole for pulmonary mucormycosis in persistent febrile neutropenia: A case report;Uzun süren febril nötropenili bir olguda akciǧer mukormikozu ve posakonazol kullanımı

Klimik Dergisi

Volumn 24, Issue 1, 2011, Pages 57-61

  Erbay Apaydin, Fatma ^a   Orhan, Bülent ^a   Bilgi, Selçuk ^b   Akalin, Halis ^c  

^a Acibadem Bursa Hastanesi   (Turkey)

^b ACIBADEM UNIVERSITY   (Turkey)

^c ULUDAG UNIVERSITY   (Turkey)

Author keywords

Fungal lung diseases; Mucormycosis; Neutropenia; Posaconazole

Indexed keywords

AMPHOTERICIN B; POSACONAZOLE;

ARTICLE; CASE REPORT; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; LUNG MYCOSIS; MUCORMYCOSIS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 83655190969     PISSN: 1301143X     EISSN: 13091484     Source Type: Journal    
DOI: 10.5152/kd.2011.12     Document Type: Article

References (14)

1. Kontoyiannis DP, Lewis RE. Agent of mucormycosis and entomophthoramycosis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone Elsevier, 2010: 3257-69.
2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41(5): 634-53.
3. Ener B. Mukormikoz etkenleri. In: Willke Topcu A, Söyletir G, Doǧanay M, eds. Enfeksiyon Hastali{dotless}klari{dotless} ve Mikrobiyolojisi. 3. baski{dotless}. İstanbul: Nobel Ti{dotless}p Kitabevleri, 2008: 2452-8.
4. Ravandi F, O'Brien S. Infections associated with purine analogs and monoclonal antibodies. Blood Rev. 2005; 19(5): 253-73. [Crossref]
5. Taşbakan MS, Çeviker Y, Sipahi OR, et al. Pansitopenik bir olguda rinoserebral ve akciǧer mukormikozu ve aspergillozu. Ankem Derg. 2010; 24(1): 42-5.
6. Bilgin M, Oǧuzkaya F, Oymak S, Canöz Ö. Akciǧer mukormikozisi: İki vakani{dotless}n sunumu. Erciyes Ti{dotless}p Derg. 2003; 25(4): 200-3.
7. Alexander BD, Phaller MA. Contemporary tools for the diagnosis and management of invazive mycoses. Clin Infect Dis. 2006; 43(Suppl. 1): S15-27.
8. Dannaoui E. Molecular tools for identification of zygomycetes and the diagnosis of zygomycosis. Clin Microbiol Infect. 2009; 15(Suppl. 5): 66-70. [Crossref]
9. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis Clin Infect Dis. 2008; 47(4): 503-9. [Crossref]
10. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 2007; 51(7): 2587-90. [Crossref]
11. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006; 42(7): e61-5. [Crossref]
12. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007; 44(1): 2-12. [Crossref]
13. Kebapci N, Efe B, Alataş F, Açikalin M, Kiraz N. Pulmonary multinodular mucormycosis in type 1 diabetic patient with diabetic ketoacidosis. J Endocrinol Invest. 2007; 30(3): 247-52.
14. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009; 48(12): 1743-51. [Crossref]